Hsa-Mir-1 and Hsa-Mir-1229 expression levels in recurrent miscarriage patients before and after lymphocyte therapy in comparison to control groups
Background. Recurrent pregnancy loss is defined as at least two consecutive clinical pregnancy losses before 20th week of gestation. In this study, we investigated microRNA-1 and microRNA-1229 in recurrent miscarriage patients before and after lymphocyte therapy in comparison to control group. Meth...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | fas |
| Published: |
Tabriz University of Medical Sciences
2024-04-01
|
| Series: | مجله پزشکی دانشگاه علوم پزشکی تبریز |
| Subjects: | |
| Online Access: | https://mj.tbzmed.ac.ir/PDF/mj-46-19.pdf |
| _version_ | 1797200640935460864 |
|---|---|
| author | Mortaza Raeisi Mehdi Yousefi Javad Ahmadian Haris Shahla Danaii Mohammad Tofighifard Pouya Bahlouli leili Aghebati-Maleki |
| author_facet | Mortaza Raeisi Mehdi Yousefi Javad Ahmadian Haris Shahla Danaii Mohammad Tofighifard Pouya Bahlouli leili Aghebati-Maleki |
| author_sort | Mortaza Raeisi |
| collection | DOAJ |
| description | Background. Recurrent pregnancy loss is defined as at least two consecutive clinical pregnancy losses before 20th week of gestation. In this study, we investigated microRNA-1 and microRNA-1229 in recurrent miscarriage patients before and after lymphocyte therapy in comparison to control group. Methods. First, a written and informed consent will be obtained from the target population of this study, who are people with RPL referring to Waliasr International Hospital. According to the standard protocol, the number of 2×107 is injected subcutaneously to patients. Real-time PCR technique will be used to check the expression level of microRNA-1 and microRNA-1229. Results. The gene expression level of micro-RNA 1 in RPL women before of lymphocyte therapy was 2.030±1.445 and the gene expression level of the same micro-RNA after the lymphocyte therapy of the mother was 1.101±0.4780. Also, the expression level of micro-RNA 1229 in these women was reported to be 2.100±0.6296 before treatment and 1.247±0.9631 after treatment with lymphocytes. This level of gene expression in control group, for micro-RNA 1 and micro-RNA 1229 genes is 1.000±0.08334 and 1.000±0.08091, respectively. Conclusion. The results of our study showed a noticeable decrease in the gene expression of microRNAs under study, both microRNAs 1 and 1229, in women with a history of three consecutive injections of the father's subcutaneous lymphocytes. Practical Implications. This study can show the therapeutic effect of lymphocyte for patients with recurrent miscarriage so that this treatment can be used along with other treatment methods. |
| first_indexed | 2024-04-24T07:34:52Z |
| format | Article |
| id | doaj.art-2d667c08644c47daa8e1129e351af561 |
| institution | Directory Open Access Journal |
| issn | 2783-2031 2783-204X |
| language | fas |
| last_indexed | 2024-04-24T07:34:52Z |
| publishDate | 2024-04-01 |
| publisher | Tabriz University of Medical Sciences |
| record_format | Article |
| series | مجله پزشکی دانشگاه علوم پزشکی تبریز |
| spelling | doaj.art-2d667c08644c47daa8e1129e351af5612024-04-20T08:39:33ZfasTabriz University of Medical Sciencesمجله پزشکی دانشگاه علوم پزشکی تبریز2783-20312783-204X2024-04-01461192810.34172/mj.2024.010mj-33360Hsa-Mir-1 and Hsa-Mir-1229 expression levels in recurrent miscarriage patients before and after lymphocyte therapy in comparison to control groupsMortaza Raeisi0Mehdi Yousefi1Javad Ahmadian Haris2Shahla Danaii3Mohammad Tofighifard4Pouya Bahlouli5leili Aghebati-Maleki6Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, IranDepartment of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, IranDepartment of Pediatric Diseases, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, IranGynecology Department, Eastern Azerbaijan ACECR ART Center, Eastern Azerbaijan Branch of ACECR, Tabriz, IranStem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, IranStem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, IranImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, IranBackground. Recurrent pregnancy loss is defined as at least two consecutive clinical pregnancy losses before 20th week of gestation. In this study, we investigated microRNA-1 and microRNA-1229 in recurrent miscarriage patients before and after lymphocyte therapy in comparison to control group. Methods. First, a written and informed consent will be obtained from the target population of this study, who are people with RPL referring to Waliasr International Hospital. According to the standard protocol, the number of 2×107 is injected subcutaneously to patients. Real-time PCR technique will be used to check the expression level of microRNA-1 and microRNA-1229. Results. The gene expression level of micro-RNA 1 in RPL women before of lymphocyte therapy was 2.030±1.445 and the gene expression level of the same micro-RNA after the lymphocyte therapy of the mother was 1.101±0.4780. Also, the expression level of micro-RNA 1229 in these women was reported to be 2.100±0.6296 before treatment and 1.247±0.9631 after treatment with lymphocytes. This level of gene expression in control group, for micro-RNA 1 and micro-RNA 1229 genes is 1.000±0.08334 and 1.000±0.08091, respectively. Conclusion. The results of our study showed a noticeable decrease in the gene expression of microRNAs under study, both microRNAs 1 and 1229, in women with a history of three consecutive injections of the father's subcutaneous lymphocytes. Practical Implications. This study can show the therapeutic effect of lymphocyte for patients with recurrent miscarriage so that this treatment can be used along with other treatment methods.https://mj.tbzmed.ac.ir/PDF/mj-46-19.pdflymphocyte therapymicrornainflammationrecurrent pregnancy loss |
| spellingShingle | Mortaza Raeisi Mehdi Yousefi Javad Ahmadian Haris Shahla Danaii Mohammad Tofighifard Pouya Bahlouli leili Aghebati-Maleki Hsa-Mir-1 and Hsa-Mir-1229 expression levels in recurrent miscarriage patients before and after lymphocyte therapy in comparison to control groups مجله پزشکی دانشگاه علوم پزشکی تبریز lymphocyte therapy microrna inflammation recurrent pregnancy loss |
| title | Hsa-Mir-1 and Hsa-Mir-1229 expression levels in recurrent miscarriage patients before and after lymphocyte therapy in comparison to control groups |
| title_full | Hsa-Mir-1 and Hsa-Mir-1229 expression levels in recurrent miscarriage patients before and after lymphocyte therapy in comparison to control groups |
| title_fullStr | Hsa-Mir-1 and Hsa-Mir-1229 expression levels in recurrent miscarriage patients before and after lymphocyte therapy in comparison to control groups |
| title_full_unstemmed | Hsa-Mir-1 and Hsa-Mir-1229 expression levels in recurrent miscarriage patients before and after lymphocyte therapy in comparison to control groups |
| title_short | Hsa-Mir-1 and Hsa-Mir-1229 expression levels in recurrent miscarriage patients before and after lymphocyte therapy in comparison to control groups |
| title_sort | hsa mir 1 and hsa mir 1229 expression levels in recurrent miscarriage patients before and after lymphocyte therapy in comparison to control groups |
| topic | lymphocyte therapy microrna inflammation recurrent pregnancy loss |
| url | https://mj.tbzmed.ac.ir/PDF/mj-46-19.pdf |
| work_keys_str_mv | AT mortazaraeisi hsamir1andhsamir1229expressionlevelsinrecurrentmiscarriagepatientsbeforeandafterlymphocytetherapyincomparisontocontrolgroups AT mehdiyousefi hsamir1andhsamir1229expressionlevelsinrecurrentmiscarriagepatientsbeforeandafterlymphocytetherapyincomparisontocontrolgroups AT javadahmadianharis hsamir1andhsamir1229expressionlevelsinrecurrentmiscarriagepatientsbeforeandafterlymphocytetherapyincomparisontocontrolgroups AT shahladanaii hsamir1andhsamir1229expressionlevelsinrecurrentmiscarriagepatientsbeforeandafterlymphocytetherapyincomparisontocontrolgroups AT mohammadtofighifard hsamir1andhsamir1229expressionlevelsinrecurrentmiscarriagepatientsbeforeandafterlymphocytetherapyincomparisontocontrolgroups AT pouyabahlouli hsamir1andhsamir1229expressionlevelsinrecurrentmiscarriagepatientsbeforeandafterlymphocytetherapyincomparisontocontrolgroups AT leiliaghebatimaleki hsamir1andhsamir1229expressionlevelsinrecurrentmiscarriagepatientsbeforeandafterlymphocytetherapyincomparisontocontrolgroups |